>8500
Patients across the United States and
Canada have registered to participate
in Count Me In research projects.
Partner with our community of patients, researchers, advocacy groups, and companies
working together to advance cancer treatment.
Solving the challenges of living with complex diseases involves assembling the right pieces of a complex puzzle, bringing patients, advocates, researchers, and industry partners together, and empowering them with advanced tools to conduct clinical research studies.
Count Me In has developed the resources to advance scientific collaboration through partnerships. Through these partnerships and carefully conducted studies, we have generated data that has led to numerous scientific publications and data releases that are improving the complex diseases patients journey.
Patients across the United States and
Canada have registered to participate
in Count Me In research projects.
Releases of data into
scientific repositories across
existing Count Me In projects.
Scientists working in academic and industry
settings around the world who are using
Count Me In data to catalyze their research.
Studies in collaboration with researchers across academia, industry, and patient advocacy groups, resulting in significant translational impacts.
Citations of Count Me In
datasets to date.
Patients across the United States and
Canada have registered to participate
in Count Me In research projects.
Releases of data into
scientific repositories across
existing Count Me In projects.
Scientists working in academic and industry
settings around the world who are using
Count Me In data to catalyze their research.
Studies in collaboration with researchers across academia, industry, and patient advocacy groups, resulting in significant translational impacts.
Citations of Count Me In
datasets to date.
Count Me In would like to thank each patient and patient advocacy group that has engaged or is participating in our studies. Without your invaluable contributions, achieving our vision of building a platform for the global community of patients and scientific partners that accelerates biomedical research would not be possible.
Christina Ip-Toma, Director of Scientific Programs, MIB Agents